Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 109 OC5.6 | DOI: 10.1530/endoabs.109.OC5.6

SFEBES2025 Oral Communications Adrenal and Cardiovascular (6 abstracts)

Salivary cortisone vs serum cortisol in the overnight dexamethasone suppression test: results of a utility evaluation at one centre

Mathilde Mordaunt 1 , Adrian Heald 2 , Waseem Majeed 2 , Rupindar Kochhar 2 , Akheel Syed 2 , Fahmy Hanna 3 , Brian Keevil 1 & Anthony Fryer 4


1University of Manchester, Manchester, United Kingdom; 2Salford Royal Hospital, Salford, United Kingdom; 3University Hospital North Midlands, Stoke on-Trent, United Kingdom; 4Keele University, Keele, United Kingdom


Introduction: Saliva hormone measurements are increasingly being applied in every day clinical practice. In relation to salivary cortisol / cortisone measurement there is a particular advantage, with minimal chance of cross reaction with prescribed glucocorticoids and greater convenience. We here evaluated the utility of these measurements in patients undergoing an overnight dexamethasone suppression test (ONDST).

Methods: Individuals undergoing an ONDST had parallel measurement of serum cortisol and salivary cortisone at 0900 following midnight dexamethasone(1 mg). Salivary cortisone was measured by electrospray positive ion mode liquid chromatography tandem mass spectrometry (1). The threshold for adequate suppression of salivary cortisone was<2.7 nmol/l; serum cortisol was<50nmol/l.

Results: Results for 25 individuals (24% men (median age 53.0) and 76% women (median age 55.6) were analysed. In 40% of individuals an adrenal adenoma was present; in 53% Cushing’s Syndrome was suspected on the basis of clinical features. Serum cortisol failed to suppress <50 nmol/l in 14/25 cases. We found a strong correlation between 0900 salivary cortisone and serum cortisol after 1 mg ONDST (beta coefficient=0.31, [95% CI 1.4-4.9], P=0.001). When performance of post-dexamethasone salivary cortisone (<2.7 nmol/l) alone in relation to suppression of serum cortisol (<50 nmol/l) was analysed, agreement was 72.3% between tests (Cohens Kappa 0.30 P=0.02), with a positive predictive value of 70% of salivary cortisone (using serum cortisol as the standard) and negative predictive value of 100% in relation to ruling out cortisol excess.

Conclusion: We have demonstrated test validity and clinical utility in substitution of salivary cortisone for serum cortisol in the ONDST as a first-line test. Salivary cortisone could therefore be used as an alternative sampling method which does not require venepuncture or attendance at hospital. Application of the test has the potential for significant savings of money and time.Reference: Jones RL et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;881-882:42-48. doi:10.1016/j.jchromb.2011.11.036

Volume 109

Society for Endocrinology BES 2025

Harrogate, UK
10 Mar 2025 - 12 Mar 2025

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches